UNH stock holds near support after recent earnings pressure

UNH stock is still being judged against UnitedHealth Group's 2025 operating base, where full-year revenue reached $400.3 billion and adjusted earnings per share came in at $29.74. The company also reported 2025 cash flows from operations of $24.2 billion, giving the market a concrete reference point for the latest valuation debate.

2025 numbers set the bar

UnitedHealth Group's 2025 revenue of $400.3 billion was paired with a reported net margin that remained under pressure from medical cost trends, while adjusted EPS of $29.74 showed the scale of earnings power in a large managed-care model. Cash flows from operations of $24.2 billion added another dated measure of financial strength in the latest annual cycle.

The comparison matters because the 2025 revenue base gives investors a fresh benchmark for any slowdown or rebound in 2026, and the EPS figure anchors expectations around profitability rather than headline membership growth alone. For a company of this size, even small changes in margin discipline can move sentiment quickly.

Revenue and cash flow matter

UnitedHealth Group's scale is built on managed care, Optum services, and pharmacy-related operations, so the most useful numbers are still the ones that show how those parts convert into revenue and cash generation. The 2025 operating cash flow figure of $24.2 billion is especially relevant because it shows how much liquidity the business generated before capital allocation and future investment decisions.

For investors, the key question is whether 2026 can preserve that cash profile while keeping medical costs and reimbursement trends contained. That is the number set that matters most now: $400.3 billion of revenue, $29.74 of adjusted EPS, and $24.2 billion of operating cash flow, all for 2025.

Optum stays central

Optum remains the most important product and service complex inside UnitedHealth Group because it connects care delivery, data, and pharmacy services. The segment is a major reason the company is able to report such large-scale revenue and cash generation in a single year.

That mix also makes the group sensitive to execution at the clinic, services, and pharmacy levels, since each piece influences margin quality. The 2025 figures show the business still has size and earnings capacity, but the market will keep measuring whether that capacity translates into steadier 2026 performance.

Stock level watch

UNH stock is usually traded as a market story about earnings quality, not just membership count, so the 2025 revenue and EPS figures remain the most relevant anchor for valuation. In that context, the latest annual cash flow of $24.2 billion is the cleanest reminder that the company is still capable of producing substantial internal funding.

The share price line is omitted here because no dated market quote was available in the evidence set. The body text instead keeps the focus on the documented 2025 operating figures that define the current setup.

Product and service core

UnitedHealthcare, Optum, and the company's broader managed-care and services platform are the core business drivers behind the numbers. Their combined scale is reflected in the 2025 revenue of $400.3 billion and the adjusted EPS of $29.74, which together show why the company remains a heavyweight in US health care.

Trading snapshot

UNH stock is a US-listed large-cap health care name centered on UnitedHealth Group. The latest evidenced market value was not available in the search results, so the article tracks the better-supported 2025 operating metrics instead.